Labiana Health

Labiana Health CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Labiana Health (LAB.MC) as of Nov 19, 2026 is 261.08 %. In the previous year, CapEx to Operating Cash Flow Ratio was 42.37 % — a change of 516.25% (higher).

CapEx/OCF

261.08 %

YoY

516.25%

Last updated:

CapEx to Operating Cash Flow Ratio of Labiana Health is 2025 261.08 % . CapEx to Operating Cash Flow Ratio of Labiana Health was 2024 42.37 % . It decreases by 516.25% higher compared to the previous year.

The Labiana Health CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
417.11 EUR
Jan 1, 2019
-568.72 EUR
Jan 1, 2021
121.98 EUR
Jan 1, 2022
116.55 EUR
Jan 1, 2023
-156.13 EUR
Jan 1, 2024
42.37 EUR
Jan 1, 2025
261.08 EUR
The Labiana Health CapEx/OCF history
YEARCapEx/OCFYoY
261.08 %+516.25%
42.37 %-127.14%
-156.13 %-233.95%
116.55 %-4.45%
121.98 %-121.45%
-568.72 %-236.35%
417.11 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labiana Health Stock analysis

What does Labiana Health do? Labiana Health SA generates revenue through the development, manufacturing, and marketing of animal and human medicines. The company focuses on drug research and development, including galenic and analytical development, as well as drug manufacturing, which encompasses formulation development and bacterial vaccine manufacturing. Regulatory services for pharmaceutical product registration in global markets also contribute to its income. Its subsidiaries operate in Ecuador, Mexico, Serbia, and Turkey, serving markets for both animal and human pharmaceutical products. The company's primary products include sterile and lyophilized dosage forms, which are manufactured for use in animal and human medicine. These products are sold to customers in the pharmaceutical industry, including distributors and healthcare providers in the regions where Labiana Health SA has a presence. The company’s R&D and manufacturing capabilities support the production of medicines that meet regulatory standards for global markets. Labiana Health SA’s business model relies on its subsidiaries in Ecuador, Mexico, Serbia, and Turkey to facilitate market access and distribution. The company’s revenue streams are derived from the sale of pharmaceutical products, regulatory services, and the development of new drug formulations. Its focus on sterile and lyophilized dosage forms positions it within the specialized pharmaceutical manufacturing sector, targeting both animal and human medicine segments. Labiana Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labiana Health stock

CapEx to Operating Cash Flow Ratio of Labiana Health is 261.08 % in 2025.

CapEx to Operating Cash Flow Ratio of Labiana Health changed from 42.37 % to 261.08 %, representing a 516.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Labiana Health since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Labiana Health with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Labiana Health

All Key Metrics — Labiana Health